Brief: Sarepta Therapeutics To Report 3-Year Topline Data From Embark Study Of Elevidys Gene Therapy
23/01/2026 21:43
Jan 23 (Reuters) - Sarepta Therapeutics Inc SRPT.O: SAREPTA THERAPEUTICS TO REPORT 3-YEAR TOPLINE DATA FROM EMBARK STUDY OF ELEVIDYS GENE THERAPY IN AMBULATORY INDIVIDUALS WITH DUCHENNE MUSCULAR DYSTROPHY Source text: ID:nBw8fvM0ma Further company coverage: SRPT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sarepta Therapeutics
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
Sarepta, Dyne fall after Novartis muscle disorder trial failure